One-year infection control rates of a DAIR (debridement, antibiotics and implant retention) procedure after primary and prosthetic-joint-infection-related revision arthroplasty - A retrospective cohort study

Journal Article (2021)
Author(s)

F. Ruben H.A. Nurmohamed (University Medical Center Utrecht)

B van Dijk (University Medical Center Utrecht)

Ewout S. Veltman (University Medical Center Utrecht)

Marrit Hoekstra (University Medical Center Utrecht)

Rob J. Rentenaar (University Medical Center Utrecht)

Harrie Weinans (University Medical Center Utrecht, TU Delft - Biomaterials & Tissue Biomechanics)

Charles Vogely (University Medical Center Utrecht)

B. C.H. Van Der Wal (University Medical Center Utrecht)

Research Group
Biomaterials & Tissue Biomechanics
Copyright
© 2021 F. Ruben H.A. Nurmohamed, Bruce Van Dijk, Ewout S. Veltman, Marrit Hoekstra, Rob J. Rentenaar, Harrie Weinans, H. Charles Vogely, Bart C.H. Van Der Wal
DOI related publication
https://doi.org/10.5194/jbji-6-91-2021
More Info
expand_more
Publication Year
2021
Language
English
Copyright
© 2021 F. Ruben H.A. Nurmohamed, Bruce Van Dijk, Ewout S. Veltman, Marrit Hoekstra, Rob J. Rentenaar, Harrie Weinans, H. Charles Vogely, Bart C.H. Van Der Wal
Research Group
Biomaterials & Tissue Biomechanics
Issue number
4
Volume number
6
Pages (from-to)
91-97
Reuse Rights

Other than for strictly personal use, it is not permitted to download, forward or distribute the text or part of it, without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license such as Creative Commons.

Abstract

Introduction: Debridement, antibiotics and implant retention (DAIR) procedures are effective treatments for acute postoperative or acute hematogenous periprosthetic joint infections. However, literature reporting on the effectiveness of DAIR procedures performed after a one- or two-stage revision because of a prosthetic joint infection (PJI) (PJI-related revision arthroplasty) is scarce. The aim of this study is to retrospectively evaluate the infection control after 1 year of a DAIR procedure in the case of an early postoperative infection either after primary arthroplasty or after PJI-related revision arthroplasty. Materials and methods: All patients treated with a DAIR procedure within 3 months after onset of PJI between 2009 and 2017 were retrospectively included. Data were collected on patient and infection characteristics. All infections were confirmed by applying the Musculoskeletal Infection Society (MSIS) 2014 criteria. The primary outcome was successful control of infection at 1 year after a DAIR procedure, which was defined as the absence of clinical signs, such as pain, swelling, and erythema; radiological signs, such as protheses loosening; or laboratory signs, such as C-reactive protein (CRP) (<10) with no use of antibiotic therapy. Results: Sixty-seven patients were treated with a DAIR procedure (41 hips and 26 knees). Successful infection control rates of a DAIR procedure after primary arthroplasty (n=51) and after prior PJI-related revision arthroplasty (n=16) were 69 % and 56 %, respectively (p=0.38). The successful infection control rates of a DAIR procedure after an early acute infection (n=35) and after a hematogenous infection (n=16) following primary arthroplasty were both 69 % (p=1.00). Conclusion: In this limited study population, no statistically significant difference is found in infection control after 1 year between DAIR procedures after primary arthroplasty and PJI-related revision arthroplasty.